---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009155"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:40:29.669671+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals to acquire SKNY; combined enterprise value over $60M

## Summary
- Board unanimously approved definitive agreement to acquire SKNY on April 30, 2025.
- Third-party valuation assigned SKNY enterprise value of ~$30.5M; MIRA ~$30M.
- SKNY to contribute $5M in assets or cash at closing with no contingencies.
- Combined enterprise value exceeds $60M, creating a broader platform targeting obesity and nicotine dependence.
- MIRA preparing to file proxy statement to seek shareholder approval.

## SEC filing metadata
- accession: 0001641172-25-009155
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225009155/0001641172-25-009155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225009155/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009155
- JSON: https://secwatch.observer/filing/0001641172-25-009155.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.